800 Pharma

800Pharma is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies by leveraging its proprietary pH-sensitive drug delivery platform. The company's technology is designed to selectively release potent therapeutic agents within the acidic environment of solid tumors, thereby enhancing efficacy while minimizing systemic toxicity. Its lead candidate, 800P-001, is a pH-sensitive prodrug currently being evaluated in clinical trials for various solid tumor indications. 800Pharma maintains operations in both China and the United States, aiming to address significant unmet needs in oncology through its "smart" drug design.